Asthma and lower airway diseaseTreatment adherence in asthmatic patients: The last frontier?
References (12)
- et al.
Uniform definition of asthma severity, control and exacerbations: document presented for the World Health Organisation consultation on severe asthma
J Allergy Clin Immunol
(2010) - et al.
Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial
J Allergy Clin Immunol Pract
(2013) - et al.
Randomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting beta-agonist inhaler therapy in asthma
J Allergy Clin Immunol
(2010) - et al.
Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial
Lancet Respir Med
(2013) - et al.
International ERS/ATS Guidelines on definition, evaluation and treatment of severe asthma
Eur Respir J
(2014) - et al.
Compliance with inhaled medications: the relationship between diary and electronic monitoring
Ann Behav Med
(1998)
There are more references available in the full text version of this article.
Cited by (8)
GINA Implementation Improves Asthma Symptoms Control and Lung Function: A Five-Year Real-World Follow-Up Study
2023, Journal of Personalized MedicineWhat convinces parents of children with asthma to adhere to maintenance inhaled corticosteroids?
2018, Canadian Journal of Respiratory, Critical Care, and Sleep MedicinePrevalence of asthma-like symptoms with ageing
2018, ThoraxThe future of inhalers: how can we improve drug delivery in asthma and COPD?
2016, Expert Review of Respiratory MedicineA review of standard pharmacological therapy for adult asthma - Steps 1 to 5
2015, Chronic Respiratory Disease
Disclosure of potential conflict of interest: E. D. Bateman's institution has received funding from Boehringer Ingelheim, AstraZeneca, Almirall, Novartis, Merck, Takeda, Actelion, Aeras, Chiesi, Cephalon, Sanofi-Aventis, TEVA, and Glaxo SmithKline; he has received compensation for board membership and/or delivering lectures from AstraZeneca, Elevation Pharma, Napp Pharma, Novartis, Almirall, Forest, Merck, Takeda, GlaxoSmithKline, Chiesi, Nycomed, and Pfizer; and he has received consultancy fees from Navigant Consulting, the IMS Consulting Group, ALK-Abelló, Hoffmann la Roche, ICON, Actelion, Aeras, and Cephalon.
Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.